Vistagen Therapeutics, Inc.
Get Full AccessDescription
- VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders. VistaGen's lead CNS product candidate, AV-101, is a new generation oral antidepressant drug candidate in Phase 2 development. AV-101's mechanism of action is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the U.S. National Institute of Mental Health (NIMH) in a Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with inadequate response to standard, FDA-approved antidepressants. Dr. Maurizio Fava of Harvard University will be the Principal Investigator of the Company's Phase 2 adjunctive treatment study. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including chronic neuropathic pain, epilepsy, Parkinson's disease and Huntington's disease, where modulation of the NMDAR, AMPA pathway and/or key active metabolites of AV-101 may achieve therapeutic benefit.VistaStem Therapeutics is VistaGen's wholly owned subsidiary focused on applying human pluripotent stem cell technology, internally and with collaborators, to discover, rescue, develop and commercialize proprietary new chemical entities (NCEs), including small molecule NCEs with regenerative potential, for CNS and other diseases, and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells.
-
Headquarters:343 Allerton Avenue , South San Francisco, California, United States
More -
Phone Number: +1 650-244-9990
-
Website: https://www.vistagen.com
-
Employees:16
-
Revenue:$1 - 10M
-
Legal Name:Vistagen Therapeutics, Inc.
-
Vistagen Therapeutics, Inc.'s Social Media
-
Is this data correct?
-
| NAICS Code: 325412 |
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
View Employees
Frequently Asked Questions regarding Vistagen Therapeutics, Inc.
-
Where are Vistagen Therapeutics, Inc.'s Headquarters?
Vistagen Therapeutics, Inc.'s Headquarters are in 343 Allerton Avenue ,South San Francisco,California,United States
-
What is Vistagen Therapeutics, Inc.'s phone number?
Vistagen Therapeutics, Inc.'s phone number is +1 650-244-9990
-
What is Vistagen Therapeutics, Inc.'s official website?
Vistagen Therapeutics, Inc.'s official website is https://www.vistagen.com
-
What is Vistagen Therapeutics, Inc.'s Revenue?
Vistagen Therapeutics, Inc.'s revenue is $1 - 10M
-
What is Vistagen Therapeutics, Inc.'s NAICS code?
Vistagen Therapeutics, Inc.'s NAICS code is 325412
-
How many employees are working in Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc. has 16 employees
-
What is Vistagen Therapeutics, Inc.'s Industry?
Vistagen Therapeutics, Inc. is in the industry of Pharmaceuticals
-
Who is Vistagen Therapeutics, Inc.'s President, Chief Scientific Officer, Founder?
Vistagen Therapeutics, Inc.'s President, Chief Scientific Officer, Founder is Ralph Snodgrass